RAPP · Rapport Therapeutics Inc
United States · RS rating 21 · As of 2026-11-03
| Price | 25.44 USD |
|---|---|
| 1-day change | +1.2% |
| RS rating (overall / 1M / 3M / 12M) | 21 / 20 / 13 / 42 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 27 / 15 / 11 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -1.4% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +51.5% |
| Market cap (USD) | $1.7B |